Investigation of serum survivin in dogs suffering from cancer: a multicenter study |
| |
Authors: | Annkathrin Estaller Martin Kessler Axel Wehrend Frank Gessler Johannes Hirschberger Stephan Neumann |
| |
Affiliation: | 1.Small Animal Clinic, Institute of Veterinary Medicine, Georg-August University of Göttingen, Göttingen 37077, Germany.;2.Small Animal Clinic Hofheim, Hofheim am Taunus 65719, Germany.;3.Clinic of Obstetrics, Gynaecology and Andrology of Large and Small Animals of the Justus-Liebig-University Giessen, Giessen 35392, Germany.;4.Miprolab GmbH, Göttingen 37079, Germany.;5.Clinic of Small Animal Medicine, Ludwig Maximilian University of Munich, Munich 80539, Germany. |
| |
Abstract: | BackgroundIn contrast to human medicine, only a small number of serum tumor markers are established in veterinary medicine even though they are a non-invasive diagnostic tool.ObjectivesThis study examined whether survivin could be suitable as a potential canine serum tumor marker.MethodsThis study measured the serum survivin concentrations of dogs with mammary tumors (n = 33), squamous cell carcinoma (n = 9), soft-tissue sarcoma (n = 18) and multicentric lymphoma (n = 22), using a commercially available, competitive immunoassay kit (BlueGene). The serum survivin concentrations were compared with those of a healthy control group (n = 20) and a control group of dogs with non-neoplastic diseases (n = 17).ResultsDogs with malignant tumors had serum survivin concentrations between 15 and 5,906 pg/mL (median, 72 pg/mL), those in the healthy group ranged from 7 to 99 pg/mL (median, 21 pg/mL) and those in the group of dogs suffering from non-neoplastic diseases from 15 to 93 pg/mL (median, 42 pg/mL). The differences in the survivin concentrations between the healthy dogs and dogs with malignant tumors and between the dogs with non-neoplastic diseases and those with malignant tumors were significant (p < 0.001 and p = 0.006, respectively).ConclusionsThe serum survivin concentrations in dogs with malignant tumors, with some exceptions, are higher than in dogs with benign tumors and dogs that do not suffer from a malignancy. Therefore, survivin can provide information on the presence of malignant tumors and be used as a tumor marker in dogs. |
| |
Keywords: | Biomarker dog malignancy serum survivin |
|
|